Figure 6.
Median paclitaxel plasma clearance vs time profile following a 3 h i.v. administration of paclitaxel in the absence or presence of zosuquidar (Cmax≤ 350 µg l−1) (solid line) and the presence of zosuquidar (Cmax > 350 µg l−1) (dashed line)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.